News|Articles|January 19, 2022

FDA Publishes 2021 Year in Review

The agency discusses its response to COVID-19 and other milestones in its year-end review.

FDA has published its review of the accomplishments the agency achieved in 2021. FDA 2021 Year in Review–Working for You details the agency’s response to COVID-19, including vaccine, treatment, and testing authorizations. FDA has also been monitoring variants of the virus and issuing guidance and contingency plans for dealing with the pandemic. The report also discusses the agency’s efforts for addressing the misuse of prescription drugs, the problem of fraudulent medicines, and the advancement of generic drugs and biosimilars, as well as its work in food safety and tobacco products.

“While much of the attention the agency received in 2021 focused on our response to the pandemic, I am pleased to note that, despite a great deal of uncertainty, the agency was able to accomplish a wide range of its priorities that are already protecting the health and well-being of millions of people living in the US,” said Acting Commissioner Janet Woodcock, MD, in the report. “Every year the FDA reviews hundreds of product applications, ultimately determining which drugs, devices, or biological products (e.g., vaccines) will be marketed in the US. The process involved is rigorous, thoughtful and always adheres to standards for safety and effectiveness. We help to ensure that the human and animal food supply is safe, sanitary, and accurately labeled, and that cosmetic products are safe and properly labeled,” said Woodcock.

Source: FDA


Related to this article

Regulatory Roundup—September 2026
The FDA opened an expedited IND pilot, tightened scrutiny of foreign trial data, and finalized a rule recognizing non-animal testing methods. In Europe, the EMA advanced pharmaceutical legislation reform, restricted 2 legacy products, and opened an injectable-iron safety review.
Pharma Logistician Using IoT Based On Blockchain | Image Credit: ©leowolfert -stock.adobe.com
Michael Levy, senior vice president, Digital & Innovation, USP, explains the digital supply chain in a preview of his upcoming CPHI Milan panel presentation, The Next Phase of Pharma Supply Chains.